Joseph Avey, MD
Family Medicine · Lehigh Acres, FLNPI 1396732970
Payments from drug & device makers
Across 139 payments — averaging $22.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$639
- AstraZeneca$590
- Lilly USA, LLC$257
- Boehringer Ingelheim$183
- GSK$182
- Sanofi-aventis U.S. LLC$169
- plus $1K from 16 others
What the payments were for
- Food & beverage$3,064100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 32 | $639 |
| AstraZeneca | 22 | $590 |
| Lilly USA, LLC | 16 | $257 |
| Boehringer Ingelheim | 8 | $183 |
| GSK | 10 | $182 |
| Sanofi-aventis U.S. LLC | 8 | $169 |
| Merz North America, Inc. | 6 | $157 |
| Boston Scientific | 3 | $136 |
| AbbVie | 7 | $129 |
| Vanda Pharmaceuticals Inc. | 4 | $100 |
| Abbott | 4 | $89 |
| Amgen | 1 | $85 |
| Pfizer | 3 | $82 |
| Amarin Pharma, Inc. | 3 | $69 |
| Dexcom, Inc. | 3 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Johnson & Johnson | 2 | $37 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Edwards Lifesciences | 1 | $16 |
| Optinose US, Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,064 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 26 | $489,082 |
| FarxigaDapagliflozin Propanediol | 131 | $133,816 |
| OzempicSemaglutide | 75 | $132,137 |
| JardianceEmpagliflozin | 86 | $98,606 |
| EliquisApixaban | 102 | $90,157 |
| TrulicityDulaglutide | 38 | $65,733 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $48,441 |
| MounjaroTirzepatide | 30 | $32,328 |
| JanuviaSitagliptin Phosphate | 18 | $30,345 |
| RybelsusSemaglutide | 15 | $26,731 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $21,357 |
| CaplytaLumateperone Tosylate | 12 | $20,050 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $20,012 |
| LinzessLinaclotide | 14 | $19,841 |
| XareltoRivaroxaban | 19 | $16,577 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $639 | $158,86890 claims |
| AstraZenecaFarxiga, Nexium, Symbicort | $590 | $143,904153 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $183 | $112,942103 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $257 | $98,06168 claims |
| PfizerEliquis | $82 | $90,157102 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $182 | $57,53245 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $17 | $21,35712 claims |
| AbbVieLinzess | $129 | $19,84114 claims |
| Johnson & JohnsonXarelto | $37 | $16,57719 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $41 | $5,96512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Lehigh Acres
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.